$LEXX — Lexaria Bioscience
The tiny biotech aiming to solve one of the biggest problems in modern medicine: GLP-1 injections.
Lexaria’s DehydraTECH platform enhances how drugs are absorbed — faster onset, fewer side effects, better patient experience.
No new drugs. Just smarter delivery.
Applies to GLP-1s, cannabinoids, antivirals & more.
Business model: licensing to big pharma.
The Big Bet — Oral GLP-1s
GLP-1 drugs like Ozempic & Wegovy dominate a $40B+ market.
But injections + side effects = major friction.
Lexaria is targeting oral alternatives with improved tolerability — and early data is promising.
Clinical Highlights
→ Up to 48% fewer adverse events vs oral semaglutide
→ Up to 67% less nausea vs injectable liraglutide
→ Comparable blood sugar control across studies
⚠️ Watch: weight loss efficacy still needs improvement
IP Strength
→ 60+ patents globally
→ Protection into 2043+
→ Early pharma discussions underway
2026 Catalysts
→ New human GLP-1 study underway (results Q4 2026)
→ Animal studies unlocking new formulations
→ Earnings momentum building
Snapshot
→ ~$18M market cap
→ Pre-revenue, high burn
→ Funded through 2026 (for now)
🟢 Platform potential across multiple drug classes
🟢 Massive TAM + licensing upside
This is a pure binary biotech bet.
If clinical data holds + a pharma deal lands → massive upside.
High risk. High reward.
Not a financial advice. DYOR
#Biotech #Investing #SmallCaps #Healthcare #Stocks #HighRiskHighReward #GLP1 #Pharma #StockMark
